Drug Profile
Research programme: endopeptidase inhibitors - American Life Science Pharmaceuticals
Alternative Names: acetyl-L-leucyl-L-valyl-L-lysinal-aldehyde; ALP 496; ALSP Next generation compounds; CA 074Me; E 64dLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator American Life Science Pharmaceuticals; Columbia University; University of Illinois at Chicago
- Class Neuropeptides; Small molecules
- Mechanism of Action Amyloid precursor protein secretase modulators; Cathepsin B inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Traumatic brain injuries
Most Recent Events
- 22 Feb 2023 Preclinical development in Alzheimer's-disease is ongoing in USA (American Life Science Pharmaceuticals website, February 2023)
- 22 Feb 2023 Preclinical development in Traumatic brain injuries is ongoing in USA (American Life Science Pharmaceuticals website, February 2023)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Traumatic brain injuries in USA